Ovarian Cancer Coverage from Every Angle

Yoland C. Antill, MD, on the Potential Role for Durvalumab in Treating Advanced Endometrial Cancer

Posted: Monday, June 10, 2019

Yoland C. Antill, MD, of Cabrini Health, discusses the potential role for the PD-L1 inhibitor durvalumab as monotherapy for recurrent or advanced endometrial cancer, based on phase II data from the PHAEDRA trial.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.